Mining bacterial genomes for antimicrobial targets.
The elucidation of whole-genome sequences is expected to have a revolutionary impact on the discovery of novel medicines. With the availability of complete genome sequences of more than 30 different species, the field of antimicrobial drug discovery has the opportunity to access a remarkable diversity of genomic information. In this review, I summarize how microbial genomics has changed strategies of drug discovery by applying bioinformatics, novel genetic approaches and genomics-based technologies, including analysis of gene expression using DNA microarrays.
Loferer
H
H
GPC Biotech AG, Fraunhoferstrasse 20, D-82152 Martinsried/Munich, Germany. Hannes.Loferer@gpc-biotech.com
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D001709:Biotechnology / Q000379:methods; D019295:Computational Biology / Q000379:methods; D015195:Drug Design; D016680:Genome, Bacterial
D000900:Anti-Bacterial Agents